By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Live Trading NewsLive Trading NewsLive Trading News
  • Stocks
  • Forex
  • Gold
  • KNIGHTS
  • Luxury
  • Horse Racing
  • Trade Now
Search
Reading: Sitting on a Cash Pile 13.0? This Bio-Tech is Focused on Discovering and Developing Cancer Immunotherapies
Share
Live Trading NewsLive Trading News
  • Stocks
  • Forex
  • Gold
  • KNIGHTS
  • Luxury
  • Horse Racing
  • Trade Now
Search
  • Stocks
  • Forex
  • Gold
  • KNIGHTS
  • Luxury
  • Horse Racing
  • Trade Now
Follow US
© 2024 LiveTradingNews.com - All Rights Reserved.
Live Trading News > Blog > 2021 > Sitting on a Cash Pile 13.0? This Bio-Tech is Focused on Discovering and Developing Cancer Immunotherapies
2021

Sitting on a Cash Pile 13.0? This Bio-Tech is Focused on Discovering and Developing Cancer Immunotherapies

Paul Ebeling
Last updated: March 31, 2021 10:07 pm
Paul Ebeling
Share
3 Min Read
cash96279e06 abda 4297 b5ee 42f118f81b5c 1 1 1
SHARE

#cash #bullish #buy

$AFMD

Affimed NV (NASDAQ:AFMD) broke out on 10 March at 6.88 and confirmed on 31 March at 7.91. Thus, garnering a LTN Cash Pile Buy rating with a 1 yr price target at 12.54. The Street’s consensus target is at 12.36.

AFMD closed Wednesday at 7.91 within 52-wk range of 1.50 – 8.60.

The Key support is at 7.63 and the resistance is Nil beyond 8.48.

Our outlook is Bullish with a Very Bullish bias in here, as the Fibo technical indicator tuned Very Bullish Wednesday.

candle

Affimed NV is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, a natural killer cell (NK-cell) TandAb, which has completed Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma.

The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager for the treatment of advanced cancer patients; AFM26, an innate cell-engaging bispecific antibody targeting B cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific antibodies for the treatment of multiple myeloma. In addition, it is developing AFM11, a T cell engager for the treatment of CD19+ B cell malignancies, including non-Hodgkin Lymphoma and acute lymphocytic leukemia (AML); and AMV564, a CD33/CD3-specific T-cell TandAb that is in Phase 1 clinical study of refractory AML.

The company has license agreements with Amphivena Therapeutics, Inc., Deutsches Krebsforschungszentrum, and Xoma Corporation; research funding agreement with The Leukemia & Lymphoma Society; and collaboration with Merck Sharp & Dohme B.V. and Roche.

It also has a clinical development and commercialization collaboration with The University of Texas MD Anderson Cancer Center to evaluate AFM13 in combination with MD Anderson’s NK-cell product; Genentech; and Roivant Sciences.

The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed NV in October 2014. Affimed N.V. was founded in Y 2000 and is HQ’d in Heidelberg, Germany

Have a healthy day, Keep the Faith!

You Might Also Like

Quo Vadis : Are you happy?

Pharrell’s Spring/Summer 2026 Louis Vuitton Menswear Collection: Another Massive Miss

Detailed History of Iran Israel Wars and Ceasefires

Iran Strikes U.S. Bases in Qatar and Iraq

Understanding the Dow Jones Industrial Average

TAGGED:AFMDBullishbuycancercashHodgkinimmunotherapieslymphomasupport

Sign Up For Daily Newsletter

Be keep up! Get the latest breaking news delivered straight to your inbox.

Subscribe our newsletter for latest news around the world. Let's stay updated!

By signing up, you agree to our Terms of Use and acknowledge the data practices in our Privacy Policy. You may unsubscribe at any time.
Share This Article
Facebook Twitter Copy Link Print
Share
By Paul Ebeling
Paul A. Ebeling, a polymath, excels, in diverse fields of knowledge Including Pattern Recognition Analysis in Equities, Commodities and Foreign Exchange, and he is the author of "The Red Roadmaster's Technical Report on the US Major Market Indices, a highly regarded, weekly financial market commentary. He is a philosopher, issuing insights on a wide range of subjects to over a million cohorts. An international audience of opinion makers, business leaders, and global organizations recognize Ebeling as an expert.   
Previous Article 442adf22d427b0e3e3b2a7a2b04e3a08 Mr. Biden to Begin Laying Out Plans for Fixing the US’ Aging Infrastructure
Next Article Saudi Arabia is about to Boom


Latest News

Riyadh Skyline 1 scaled 1
Saudi Arabia’s Digital Revolution
Blockchain for Government Headline News Knightsbridge Insights Opinion Saudi Arabia Shayne Heffernan Shayne Heffernan Shayne Heffernan on Investments June 23, 2025
image 36
De-Dollarization Is Inevitable
America Gold Headline News Most Popular Must Read Opinion Politics Shayne Heffernan USD June 21, 2025
c0502f16 1b2b 4f96 8fe6 6f4ab5e5f43f
US Bombs Iran: Escalation and Implications
Bitcoin Gold Headline News Shayne Heffernan Shayne Heffernan on Investments Todays Trade Ideas USD June 21, 2025
GuAZEmrXcAAE9Mx
USA Bombs Iran
America Gold Headline News Middle East Opinion Politics Shayne Heffernan Shayne Heffernan June 21, 2025

Stay Connected

235.3kFollowersLike
69.1kFollowersFollow
11.6kFollowersPin
56.4kFollowersFollow
4.4kFollowersFollow
//

Stay informed with LiveTradingNews.com – your ultimate destination for timely and insightful updates on global markets, finance, and investment trends. Explore the latest news and analysis to empower your trading decisions.

Quick Link

  • About us
  • Advertise
  • Send us a tip!
  • Privacy Policy
  • Contact us

Top Categories

  • Knightsbridge Insights
  • Featured
  • Stocks
  • Shayne Heffernan
  • Lifestyle

Sign Up for Our Newsletter

Subscribe to our newsletter to get our newest articles instantly!

Subscribe our newsletter for latest news around the world. Let's stay updated!

Live Trading NewsLive Trading News
Follow US
© 2025 LiveTradingNews - For The Traders, By The Traders – All Right Reserved By Knightsbridge Group
Welcome Back!

Sign in to your account

Register Lost your password?